Wednesday, January 24, 2018

Bonti Raises $15.5M

Newport Beach-based Bonti, a biopharmaceuticals developer developing treatments for musculoskeletal pain, has raised $15.5M in a Series C funding round. The funding was led by City Hill Ventures. Bonti is developing a compound based on the botulinum neurotoxin, EB-001, aimed at use in acute pain relief. The company says it has now raised $36M in total funding. As part of the funding, Bonti said it has named David Ramsay as its new CFO; Ramsay was previously CFO at Halozyme Therapeutics, and already sites on the company's board of directors. More information »